Helius Medical Technologies Inc (TSE:HSM) – Equities researchers at Oppenheimer lifted their FY2019 earnings estimates for Helius Medical Technologies in a note issued to investors on Tuesday, November 12th. Oppenheimer analyst S. Lichtman now anticipates that the company will earn ($1.17) per share for the year, up from their previous estimate of ($1.18). Oppenheimer also issued estimates for Helius Medical Technologies’ FY2020 earnings at ($1.27) EPS and FY2021 earnings at ($1.18) EPS.
Shares of TSE HSM opened at C$1.10 on Friday. Helius Medical Technologies has a twelve month low of C$1.08 and a twelve month high of C$14.16. The company has a current ratio of 3.40, a quick ratio of 3.15 and a debt-to-equity ratio of 5.56. The company has a market capitalization of $55.44 million and a price-to-earnings ratio of -3.23. The business has a 50 day simple moving average of C$1.94 and a 200-day simple moving average of C$2.72.
Helius Medical Technologies Company Profile
Helius Medical Technologies, Inc, a neurotechnology company, focuses on developing, licensing, or acquiring noninvasive technologies for the treatment of symptoms caused by neurological disease or trauma. The company's product is Portable Neuromodulation Stimulator, a medical device in Canada for the treatment of chronic balance deficit associated with a mild to moderate traumatic brain injury.
Featured Story: What is the outlook for the FAANG stocks?
Receive News & Ratings for Helius Medical Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helius Medical Technologies and related companies with MarketBeat.com's FREE daily email newsletter.